-
1
-
-
33747141495
-
Efficacy of smoking cessation intervention among special populations: Review of the literature from 2000 to 2005
-
Doolan DM, Froelicher ES. Efficacy of smoking cessation intervention among special populations: Review of the literature from 2000 to 2005. Nurs Res 2006;55(4 suppl 1):S29-S37.
-
(2006)
Nurs Res
, vol.55
, Issue.4 SUPPL. 1
-
-
Doolan, D.M.1
Froelicher, E.S.2
-
2
-
-
0037291542
-
Smoking cessation in the elderly
-
Appel DW, Aldrich TK. Smoking cessation in the elderly. Clin Geriatr Med 2003;19(1):77-100.
-
(2003)
Clin Geriatr Med
, vol.19
, Issue.1
, pp. 77-100
-
-
Appel, D.W.1
Aldrich, T.K.2
-
3
-
-
0033864348
-
Cigarette smoking among the elderly: Disease consequences and me benefits of cessation
-
Burns DM. Cigarette smoking among the elderly: Disease consequences and me benefits of cessation. Am J Health Promot 2000; 14(6):357-361.
-
(2000)
Am J Health Promot
, vol.14
, Issue.6
, pp. 357-361
-
-
Burns, D.M.1
-
4
-
-
33645636849
-
Smoking and deaths between 40 and 70 years of age in women and men
-
Vollset SE, Tverdal A, Gjessing HK. Smoking and deaths between 40 and 70 years of age in women and men. Ann Intern Med 2006;144(6):381-389.
-
(2006)
Ann Intern Med
, vol.144
, Issue.6
, pp. 381-389
-
-
Vollset, S.E.1
Tverdal, A.2
Gjessing, H.K.3
-
5
-
-
0030000037
-
Reaching midlife and older smokers: Tailored interventions for routine medical care
-
Morgan GD, Noll EL, Orleans CT, et al. Reaching midlife and older smokers: Tailored interventions for routine medical care. Prev Med 1996;25(3):346-354.
-
(1996)
Prev Med
, vol.25
, Issue.3
, pp. 346-354
-
-
Morgan, G.D.1
Noll, E.L.2
Orleans, C.T.3
-
6
-
-
0003649181
-
The Health Benefits of Smoking Cessation
-
U.S. Department of Health and Human Services, DHHS, Washington, DC: U.S. Government Printing Office;, Publication No (CDC) 90:8416. Available at:, Accessed January 4
-
U.S. Department of Health and Human Services. The Health Benefits of Smoking Cessation: A Report of the Surgeon General (DHHS). Washington, DC: U.S. Government Printing Office; 1990: Publication No (CDC) 90:8416. Available at: www.cdc.gov/tobacco/sgr/index.htm. Accessed January 4, 2007.
-
(1990)
A Report of the Surgeon General
-
-
-
9
-
-
1642538353
-
Inpatient smoking-cessation counseling and all-cause mortality among the elderly
-
Brown D, Croft J, Schenck AP, et al. Inpatient smoking-cessation counseling and all-cause mortality among the elderly. Am J Prev Med 2004;26(2):112-118.
-
(2004)
Am J Prev Med
, vol.26
, Issue.2
, pp. 112-118
-
-
Brown, D.1
Croft, J.2
Schenck, A.P.3
-
10
-
-
0003617863
-
-
Rockville, MD: US Department of Health and Human Services, Public Health Service;
-
Fiore MC, Bailey WC, Cohen SJ, et al. Treating Tobacco Use and Dependence. Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services, Public Health Service; 2000.
-
(2000)
Treating Tobacco Use and Dependence. Clinical Practice Guideline
-
-
Fiore, M.C.1
Bailey, W.C.2
Cohen, S.J.3
-
11
-
-
25444520229
-
Pharmacotherapy for nicotine dependence
-
Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML. Pharmacotherapy for nicotine dependence. CA Cancer J Clin 2005;55(5):281-299.
-
(2005)
CA Cancer J Clin
, vol.55
, Issue.5
, pp. 281-299
-
-
Henningfield, J.E.1
Fant, R.V.2
Buchhalter, A.R.3
Stitzer, M.L.4
-
12
-
-
0035143861
-
Individual differences in preferences for and responses to four nicotine replacement products
-
West R, Hajek P, Nilsson F, et al. Individual differences in preferences for and responses to four nicotine replacement products. Psychapharmacology (Berl) 2001;153(2):225-230.
-
(2001)
Psychapharmacology (Berl)
, vol.153
, Issue.2
, pp. 225-230
-
-
West, R.1
Hajek, P.2
Nilsson, F.3
-
13
-
-
8544260343
-
Are there gender differences in smoking cessation, with and without bupropion? Pooled- and meta-analyses of clinical trials of bupropion SR
-
Scharf D, Shiffman S. Are there gender differences in smoking cessation, with and without bupropion? Pooled- and meta-analyses of clinical trials of bupropion SR. Addiction 2004;99:1462-1469.
-
(2004)
Addiction
, vol.99
, pp. 1462-1469
-
-
Scharf, D.1
Shiffman, S.2
-
14
-
-
0034929062
-
Bupropion for smoking cessation: Predictors of successful outcome
-
Dale LC, Glover ED, Sachs DP, et al. Bupropion for smoking cessation: Predictors of successful outcome. Chest 2001;119:1357-1364.
-
(2001)
Chest
, vol.119
, pp. 1357-1364
-
-
Dale, L.C.1
Glover, E.D.2
Sachs, D.P.3
-
15
-
-
0032066120
-
Treatment of depression in elderly patients: Recent advances
-
DasGupta K. Treatment of depression in elderly patients: Recent advances. Arch Fam Med 1998;7(3):274-280.
-
(1998)
Arch Fam Med
, vol.7
, Issue.3
, pp. 274-280
-
-
DasGupta, K.1
-
16
-
-
0032511735
-
A randomized trial of nortriptyline for smoking cessation
-
Prochazka AV, Weaver MJ, Keller RT, et al. A randomized trial of nortriptyline for smoking cessation. Arch Intern Med 1998;158 (18):2035-2039.
-
(1998)
Arch Intern Med
, vol.158
, Issue.18
, pp. 2035-2039
-
-
Prochazka, A.V.1
Weaver, M.J.2
Keller, R.T.3
-
17
-
-
7544250480
-
A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation
-
Prochazka AV, Kick S, Steinbrunn C, et al. A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation. Arch Intern Med 2004;164:2229-2233.
-
(2004)
Arch Intern Med
, vol.164
, pp. 2229-2233
-
-
Prochazka, A.V.1
Kick, S.2
Steinbrunn, C.3
-
18
-
-
33646481040
-
-
Gelfand EV, Cannon CP. Rimonabant: A cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol 2006;47(10):1919-1926. Epub 2006 Apr 24.
-
Gelfand EV, Cannon CP. Rimonabant: A cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol 2006;47(10):1919-1926. Epub 2006 Apr 24.
-
-
-
-
19
-
-
33745599140
-
the Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: A randomized controlled trial
-
Tonstad S, Tonnesen P, Hajek P, et al; the Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: A randomized controlled trial. JAMA 2006;296:64-71.
-
(2006)
JAMA
, vol.296
, pp. 64-71
-
-
Tonstad, S.1
Tonnesen, P.2
Hajek, P.3
-
20
-
-
33745611449
-
the Varenicline Phase 3 Study Group. Efficacy or varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial
-
Jorenby DE, Hays JT, Rigotti NA, et al; the Varenicline Phase 3 Study Group. Efficacy or varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. JAMA 2006;296:56-63.
-
(2006)
JAMA
, vol.296
, pp. 56-63
-
-
Jorenby, D.E.1
Hays, J.T.2
Rigotti, N.A.3
-
21
-
-
33745614361
-
the Varenicline Phase 3 Study Group. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial
-
Gonzales D, Rennard SI, Nides M, et al, the Varenicline Phase 3 Study Group. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA 2006; 296:47-55.
-
(2006)
JAMA
, vol.296
, pp. 47-55
-
-
Gonzales, D.1
Rennard, S.I.2
Nides, M.3
|